Clinical utility of phentermine/topiramate (Qsymia&trade;) combination for the treatment of obesity | Zendy

Jin Hee Shin | Zendy; Kishore M. Gadde | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity

Author(s) -

Jin Hee Shin,

Kishore M. Gadde

Publication year - 2013

Publication title -

diabetes metabolic syndrome and obesity

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.853

H-Index - 43

ISSN - 1178-7007

DOI - 10.2147/dmso.s43403

Subject(s) - phentermine , topiramate , weight loss , medicine , adverse effect , obesity , migraine , anesthesia , combination therapy , pharmacology , epilepsy , psychiatry

Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an anorexigenic agent, which is approved for the short-term treatment of obesity, while topiramate is approved for nonweight loss indications - seizure disorders and migraine prophylaxis. The amount of weight loss achieved with combination therapy is of a greater magnitude than what could be achieved with either agent alone. Adverse events that occur with the combination therapy are in line with the known side effect profiles of the constituent drugs; teratogenicity, a slight increase in heart rate, psychiatric and cognitive adverse effects, and metabolic acidosis are concerns.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research